Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9791485 | 0.84 | POLB (0.39) | POLBPDE2ANOS3NOS2TSHR | |
| SCHEMBL5190967 | 0.81 | LMNA (0.36) | POLBTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL7108992 | 0.79 | POLB (0.42) | POLBNOS3NOS2TSHRCASP1 | |
| SCHEMBL6310146 | 0.72 | POLB (0.37) | POLBNOS3NOS2 | |
| SCHEMBL19998489 | 0.72 | LMNA (0.38) | POLBTSHR | |
| SCHEMBL14600343 | 0.71 | ALDH1A1 (0.39) | PDE2ATSHRALDH1A1SCN5A | |
| SCHEMBL394750 | 0.70 | POLB (0.68) | POLBNOS3NOS2TSHRCASP1 | |
| SCHEMBL6542243 | 0.70 | POLB (0.42) | POLBNOS3NOS2TSHRMEN1 | |
| SCHEMBL13254949 | 0.70 | ALDH1A1 (0.50) | POLBTSHRCASP1MEN1MAPT | |
| SCHEMBL7089983 | 0.70 | PDE2A (0.32) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507827-B2 | Stereoselective method for the production of Clopidogrel | RATIOPHARM GMBH (DE) | 2009-03-24 | — | — | US | disclosed |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | RATIOPHARM GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | CYP2C19, ADH1C, TBXA2R | POLB 2869/4885PDE2A 132/4885NOS3 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.